Analysts have been eager to weigh in on the Healthcare sector with new ratings on Glaukos (GKOS), GW Pharma (GWPH) and Irhythm Technologies (IRTC).
BTIG analyst Ryan Zimmerman maintained a Hold rating on Glaukos on March 18. The company’s shares opened today at $77.31, close to its 52-week high of $79.85.
“and We thought it would be helpful to encapsulate the numerous clinical presentations, publications, and topics coming out of the American Glaucoma Society meeting in San Francisco this weekend applicable to Glaukos. We were unable to attend in person as there were numerous clinical conferences over the past week and similarly for investors, many may not have had a chance to spend the time reviewing topics related to Glaukos. We highlight the key studies and poster presentations below.”
According to TipRanks.com, Zimmerman is a top 100 analyst with an average return of 40.8% and a 72.4% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Glaukos with a $76 average price target.
See today’s analyst top recommended stocks >>
GW Pharma (GWPH)
J.P. Morgan analyst Cory Kasimov maintained a Buy rating on GW Pharma on March 18 and set a price target of $180. The company’s shares opened today at $169.43, close to its 52-week high of $182.23.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.7% and a 41.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Global Blood Therapeutics, and Allogene Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GW Pharma with a $178.86 average price target, which is a 5.6% upside from current levels. In a report issued on March 5, Piper Jaffray also reiterated a Buy rating on the stock with a $185 price target.
Irhythm Technologies (IRTC)
In a report issued on March 18, Sean Lavin from BTIG maintained a Hold rating on Irhythm Technologies, with a price target of $189. The company’s shares opened today at $91.66, close to its 52-week high of $98.37.
“From A ZIO Study (AAPL, Walter Piecyk) were revealed at ACC. For patients that received an irregular pulse notification while simultaneously wearing an Watch correctly identified afib 84% of the time. On the surface, the Watch’s predictive value was better than we expected though there are a handful of important considerations here – most importantly, the small testing size. On balance, the study highlights the feasibility of Watch’s role in driving consumer health but it is neither a diagnostic nor replacement for ECG monitors like iRhythm’s ZIO (the trial wasn’t intended to prove so). ACC, we sense this was generally understood by clinicians but also feel that docs remain skeptical of mass asymptomatic screening.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 9.9% and a 58.7% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Irhythm Technologies with a $101.14 average price target, representing a 10.3% upside. In a report issued on March 18, Northland Securities also assigned a Hold rating to the stock with a $75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.